VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...
Hosted on MSN
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly selective CDK9 inhibitor, in patients with relapsed or refractory diffuse large ...
Wave Life Sciences (WVE) announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 antitrypsin deficiency [AATD]. It was shown that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results